Does the FDA support starting HRT earlier

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, the agency supports initiating hormone therapy at an appropriate time for symptom control, particularly around the onset of menopause, because this timing is associated with a more favorable risk profile for most healthy women.

What the FDA Actually Says

According to the FDA-approved prescribing information for estrogen and progesterone therapies, these products are indicated for women experiencing bothersome menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. Because these symptoms most commonly begin during perimenopause or early postmenopause, FDA guidance effectively supports initiating treatment when symptoms arise, rather than delaying without clinical reason.

According to FDA.gov, the agency recognizes the "timing hypothesis," which indicates that beginning hormone therapy younger than 60 or within 10 years of the final menstrual period is associated with lower risks compared to initiating therapy much later. The FDA also notes in its boxed warnings that starting hormone therapy significantly after menopause may carry increased risk, particularly for clots and stroke. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

Why Earlier Use Is Considered Safer

• Blood vessels may respond more favorably earlier. According to NAMS, estrogen may work more compatibly in a cardiovascular system that has had less time to accumulate age-related changes.
• Lower baseline clot risk. Younger women may have fewer age-related clotting factors, which may contribute to a lower overall risk profile from hormone therapy.
• Symptoms are often strongest earlier. Initiating treatment when symptoms begin may allow the lowest effective dose to provide relief.
• Bone protection may be stronger. According to ACOG, early hormone therapy may help slow bone loss during the rapid decline that follows menopause.

What This Means for You

According to FDA.gov, for women in perimenopause or within approximately 10 years of their final menstrual period who are bothered by symptoms, regulatory guidance aligns with an early start where clinically appropriate. This does not mean that every woman should take hormone therapy, but for most healthy women, initiating earlier is considered both appropriate and supported by regulatory guidance. All clinical decisions should be made in consultation with a qualified prescriber.